Recently unlocked door: a fresh permission, approval, or qualification is already producing first real business
The model's full reasoning — Q2 2016 call → NO我们根据提供的会议记录内容,寻找管理层是否描述了公司最近获得了某种新的许可、批准、认证、上市或准入权,并且已经通过该新开放的门获得了首批业务,而大部分潜力还在前方。 在会议记录中,管理层提到了几个方面: - 提及了收购Plastique和Fremont,但这属于收购,不是获得外部许可。 - 提及了Doble的新产品如DM Series, Doble Prime等,但这些是新产品,未明确提及获得什么批准或认证。 - 提及了测试业务在亚洲的机会,但未提及具体批准或认证。 - 没有明确提到公司获得任何新的外部权限、批准、认证等。 因此,根据会议记录,没有发现管理层描述此类事件。答案应为NO。
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| DXCM | DexCom, Inc. | Q4 2023 | 2024-02-08 | B+ |
| RDCM | RADCOM Ltd. | Q4 2023 | 2024-01-31 | A |
| PFE | Pfizer Inc. | Q4 2023 | 2024-01-30 | F |
| NVAX | Novavax, Inc. | Q3 2023 | 2023-11-09 | F |
| RVLV | Revolve Group, Inc. | Q3 2023 | 2023-11-01 | C |
| APPS | Digital Turbine, Inc. | Q1 2024 | 2023-08-08 | D |
| SIBN | SI-BONE, Inc. | Q3 2022 | 2022-11-07 | C+ |
| HBB | Hamilton Beach Brands Holding Company | Q3 2022 | 2022-11-05 | C |
| CMLS | Cumulus Media Inc. | Q3 2022 | 2022-10-28 | D |
| YMM | Full Truck Alliance Co. Ltd. | Q2 2022 | 2022-08-25 | C+ |
| CDXC | ChromaDex Corporation | Q4 2021 | 2022-03-09 | C+ |
| VNDA | Vanda Pharmaceuticals Inc. | Q4 2021 | 2022-02-23 | F |
| AGIO | Agios Pharmaceuticals, Inc. | Q3 2018 | 2018-11-01 | C |
| AMGN | Amgen Inc. | Q3 2018 | 2018-10-30 | B+ |
| MAS | Masco Corporation | Q3 2018 | 2018-10-30 | C |
| PRIM | Primoris Services Corporation | Q2 2018 | 2018-08-11 | C+ |
| ATI | Allegheny Technologies Incorporated | Q1 2018 | 2018-04-24 | B |
| HOLX | Hologic, Inc. | Q4 2017 | 2017-11-08 | D |
| BIIB | Biogen Inc. | Q2 2017 | 2017-07-25 | B |
| CNS | Cohen & Steers, Inc. | Q2 2017 | 2017-07-20 | B |
| IONS | Ionis Pharmaceuticals, Inc. | Q1 2017 | 2017-05-09 | C |
| PDCO | Patterson Companies, Inc. | Q3 2017 | 2017-02-23 | C |
| BMY | Bristol-Myers Squibb Company | Q4 2016 | 2017-01-26 | F |
| MAT | Mattel, Inc. | Q3 2016 | 2016-10-19 | C |
NVAX · Q3 2023 → YESThe question is: Does management describe that the company RECENTLY OBTAINED A PERMISSION, APPROVAL, QUALIFICATION, CERTIFICATION, LISTING, OR ACCESS RIGHT it did not previously hold — something grant...NO The transcript describes shipments of the updated COVID vaccine that began three weeks ago in the US after competitor launches, along with EU approval in October. However, these details do not meet the criteria for a YES answer because the transcript does not explicitly frame this as a newly obtained permission or access right that the company did not previously hold. Instead, it presents the launch as an update to their existing COVID-19 vaccine platform, with references to prior versions and the ability to update for seasonal strains.
MAT · Q3 2016 → YESThe question is about whether management describes that the company recently obtained a permission, approval, etc., that it didn't previously hold, and that real first business through that newly open...YES The transcript shows management describing a recent new partnership with Toys "R" Us for American Girl, granting exclusive store-within-store access that previously excluded the company. Initial shipping began in the first full quarter, with the distribution build still in early stages and most of the market potential ahead.
MAS · Q3 2018 → YESThe question is about whether management describes that the company recently obtained a permission, approval, etc., that it didn't previously hold, and that real first business through that newly open...YES The transcript shows management describing a recent program access at Menards that enables sales of stock cabinetry, with initial performance already underway and ramping toward an $80 million annual run rate in Q4—indicating the door is newly open and most of the potential volume remains ahead.